{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:29:49Z","timestamp":1776918589678,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.antiviral.2013.06.007","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T20:31:55Z","timestamp":1371846715000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["\u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity"],"prefix":"10.1016","volume":"99","author":[{"given":"Yuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Tavis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.06.007_b0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jmb.2009.03.025","article-title":"HIV-1 reverse transcriptase can simultaneously engage its DNA\/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition","volume":"388","author":"Beilhartz","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0010","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/jm8007085","article-title":"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain","volume":"51","author":"Billamboz","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.06.007_b0015","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/jm1014692","article-title":"Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and\/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function","volume":"54","author":"Billamboz","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.06.007_b0020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/nar\/gki268","article-title":"Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones","volume":"33","author":"Budihas","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2013.06.007_b0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","article-title":"Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B","volume":"51","author":"Buti","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0030","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/JVI.70.9.6151-6156.1996","article-title":"Amino Acids Essential for RNAse H activity of hepadnaviruses are also required for efficient elongation of minus-strand DNA","volume":"70","author":"Chen","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0035","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/JVI.68.8.5232-5238.1994","article-title":"Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis","volume":"68","author":"Chen","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0040","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jmv.22014","article-title":"Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents","volume":"83","author":"Cheng","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0045","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/jm2000757","article-title":"Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H","volume":"54","author":"Chung","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.06.007_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2893.2010.01321.x","article-title":"Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy","volume":"18","author":"Coffin","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.06.007_b0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14728214.2011.646260","article-title":"Emerging pipeline drugs for hepatitis B infection","volume":"16","author":"Cox","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.antiviral.2013.06.007_b0060","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1128\/AAC.00658-11","article-title":"Expression of an Mg2+-dependent HIV-1 RNase H construct for drug screening","volume":"55","author":"Farias","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.06.007_b0065","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection \u2013 natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.06.007_b0070","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1128\/JVI.70.7.4269-4274.1996","article-title":"Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis","volume":"70","author":"Gerelsaikhan","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0075","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.06.007_b0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2180-1-12","article-title":"Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates","volume":"1","author":"Gong","year":"2001","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0085","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.str.2009.09.016","article-title":"Structure of HIV-1 reverse transcriptase with the inhibitor beta-thujaplicinol bound at the RNase H active site","volume":"17","author":"Himmel","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2013.06.007_b0090","first-page":"183","article-title":"Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target","volume":"4","author":"Klarmann","year":"2002","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2013.06.007_b0095","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1093\/nar\/gkg881","article-title":"Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors","volume":"31","author":"Klumpp","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2013.06.007_b0100","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2004.10.045","article-title":"Hepatitis B virus genotypes","volume":"23","author":"Kramvis","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2013.06.007_b0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1872-034X.2009.00601.x","article-title":"Geographical and genetic diversity of the human hepatitis B virus","volume":"40","author":"Kurbanov","year":"2010","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2013.06.007_b0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.06.007_b0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12104","article-title":"Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance","volume":"33","author":"Lee","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2013.06.007_b0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.106.025015","article-title":"Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate","volume":"71","author":"Lima","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0076-6879(01)41168-2","article-title":"Human RNases H","volume":"341","author":"Lima","year":"2001","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3851\/IMP1496","article-title":"Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy","volume":"15","author":"Lui","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.06.007_b0145","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.06.007_b0150","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ajg.2009.726","article-title":"Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop","volume":"105","author":"Monto","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0009-2797(98)00078-7","article-title":"Mechanism of mitochondrial dysfunction and cytotoxicity induced by tropolones in isolated rat hepatocytes","volume":"116","author":"Nakagawa","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.antiviral.2013.06.007_b0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/embor.2008.256","article-title":"Retroviral integrase superfamily: the structural perspective","volume":"10","author":"Nowotny","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.antiviral.2013.06.007_b0165","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2005.04.024","article-title":"Crystal structures of RNase H bound to an RNA\/DNA hybrid: substrate specificity and metal-dependent catalysis","volume":"121","author":"Nowotny","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.06.007_b0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.healthpol.2010.09.012","article-title":"The cost-effectiveness of alternative strategies against HBV in Italy","volume":"102","author":"Ruggeri","year":"2011","journal-title":"Health Policy"},{"key":"10.1016\/j.antiviral.2013.06.007_b0175","series-title":"Fields Virology","first-page":"2977","article-title":"Hepadnaviruses","author":"Seeger","year":"2007"},{"key":"10.1016\/j.antiviral.2013.06.007_b0180","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1074\/jbc.C200621200","article-title":"Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid","volume":"278","author":"Shaw-Reid","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.06.007_b0185","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","article-title":"Hepatitis B virus infection: epidemiology and vaccination","volume":"28","author":"Shepard","year":"2006","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.antiviral.2013.06.007_b0195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-150-2-200901200-00100","article-title":"National institutes of health consensus development conference statement: management of hepatitis B","volume":"150","author":"Sorrell","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2013.06.007_b0200","doi-asserted-by":"crossref","first-page":"e1003125","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.06.007_b0205","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1128\/JVI.72.7.5789-5796.1998","article-title":"The duck hepatitis B virus polymerase is activated by Its RNA packaging signal, Epsilon","volume":"72","author":"Tavis","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0210","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.06.007_b0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.06.007_b0220","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1128\/JVI.70.9.6455-6458.1996","article-title":"Relationship between Viral DNA synthesis and virion envelopment in hepatitis B viruses","volume":"70","author":"Wei","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.06.007_b0225","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.06.007_b0230","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1016\/j.bmcl.2010.08.135","article-title":"Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold","volume":"20","author":"Williams","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.06.007_b0235","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.06.007_b0240","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.06.007_b0245","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.06.007_b0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0969-2126(01)00142-3","article-title":"Recombining the structures of HIV integrase, RuvC and RNase H","volume":"3","author":"Yang","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2013.06.007_b0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/095632020401500602","article-title":"Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?","volume":"15","author":"Zoulim","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.06.007_b0260","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213001642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213001642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T14:31:17Z","timestamp":1688308277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213001642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0166354213001642"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.06.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}